Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Receptor Tyrosine Kinase (RTK) Downregulation Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LRIG1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LRIG1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed for Native Glycosylation. |
View LRIG1 Products |
| Gene Delivery | LRIG1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View LRIG1 Products |
| Benchmark Ab | Anti-LRIG1 Recombinant Antibody Recombinant positive control derived from benchmark clinical/research clones. |
View LRIG1 Products |
| Validator | LRIG1 siRNA Set Target-specific knockdown verification for functional assays. |
View LRIG1 Products |
| Related Target A | EGFR Primary downstream RTK regulated by LRIG1; critical for resistance and synergy screening. |
View EGFR Products |
| Related Target B | ERBB3 Key heterodimerization partner in ErbB signaling pathways feedback-inhibited by LRIG1. |
View ERBB3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus LRIG1 ortholog proteins available with >95% purity |
| Shedding & soluble decoy validation | Truncated ECD-Fc proteins matching natural soluble LRIG1 (sLRIG1) cleavage sites |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live LRIG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LRIG1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and soluble decoy receptor formats. As first-generation therapies targeting receptor tyrosine kinases (RTKs) encounter resistance, the next wave of R&D is targeting LRIG1's unique ability to prompt pan-ErbB degradation. Key therapeutic strategies focus on preventing LRIG1 shedding or delivering soluble LRIG1 (sLRIG1) mimics to suppress EGFR, ErbB2-4, and MET-driven malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Soluble Decoy Proteins (sLRIG1) | Academic Institutes, Biotech Startups | Glioblastoma, NSCLC | Binding affinity to EGFR/ErbB family (Need native-glycosylated ECD-Fc) |
| Monoclonal Antibodies (mAbs) | Biopharma Innovators | Solid Tumors (EGFR-mutant) | Epitope mapping & shedding inhibition assays (Need Sequence-Verified Antigens) |
| Gene Therapy / mRNA | Translational Research Consortia | Advanced Gliomas | In vitro expression verification (Need Lentivirus for Stable Cell Lines) |